Dimerix Ltd Asset Resilience Ratio
Dimerix Ltd asset resilience ratio. Dimerix Ltd (DXB) has an Asset Resilience Ratio of 74.89% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dimerix Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dimerix Ltd (2002–2025)
Asset resilience ratio of Dimerix Ltd from 2002 to 2025. This chart shows how Dimerix Ltd's Asset Resilience Ratio has changed over time. See free cash flow generation of Dimerix Ltd to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Dimerix Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Dimerix Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$68.28 Million | 74.89% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$68.28 Million | 74.89% |
Asset Resilience Insights
- Very High Liquidity: Dimerix Ltd maintains exceptional liquid asset reserves at 74.89% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Dimerix Ltd Industry Peers by Asset Resilience Ratio
Compare Dimerix Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Dimerix Ltd Asset Resilience Ratio by Year (2002–2025)
Dimerix Ltd asset resilience ratio by year from 2002 to 2025. The table below shows the annual Asset Resilience Ratio data for Dimerix Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 74.89% | AU$68.28 Million ≈ $48.32 Million |
AU$91.18 Million ≈ $64.51 Million |
+5.87pp |
| 2024-06-30 | 69.02% | AU$22.14 Million ≈ $15.67 Million |
AU$32.08 Million ≈ $22.70 Million |
+24.02pp |
| 2023-06-30 | 45.01% | AU$7.99 Million ≈ $5.65 Million |
AU$17.76 Million ≈ $12.56 Million |
-13.37pp |
| 2022-06-30 | 58.37% | AU$9.63 Million ≈ $6.81 Million |
AU$16.50 Million ≈ $11.67 Million |
+2.64pp |
| 2021-06-30 | 55.73% | AU$5.25 Million ≈ $3.71 Million |
AU$9.42 Million ≈ $6.67 Million |
-19.21pp |
| 2020-06-30 | 74.94% | AU$7.79 Million ≈ $5.51 Million |
AU$10.39 Million ≈ $7.35 Million |
+2.82pp |
| 2019-06-30 | 72.12% | AU$3.56 Million ≈ $2.52 Million |
AU$4.94 Million ≈ $3.50 Million |
-14.38pp |
| 2018-06-30 | 86.50% | AU$6.28 Million ≈ $4.45 Million |
AU$7.26 Million ≈ $5.14 Million |
+8.35pp |
| 2017-06-30 | 78.16% | AU$2.24 Million ≈ $1.59 Million |
AU$2.87 Million ≈ $2.03 Million |
+44.28pp |
| 2013-06-30 | 33.88% | AU$594.05K ≈ $420.33K |
AU$1.75 Million ≈ $1.24 Million |
-50.95pp |
| 2012-06-30 | 84.83% | AU$1.03 Million ≈ $728.83K |
AU$1.21 Million ≈ $859.19K |
+58.22pp |
| 2011-06-30 | 26.60% | AU$424.00K ≈ $300.01K |
AU$1.59 Million ≈ $1.13 Million |
+10.73pp |
| 2002-06-30 | 15.87% | AU$300.00K ≈ $212.27K |
AU$1.89 Million ≈ $1.34 Million |
-- |
About Dimerix Ltd
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is… Read more